Comment from Anonymous

I am writing to submit a formal comment in enthusiastic support of the Food and Drug Administration's (FDA) attention to this critical therapeutic space. I strongly urge the agency to use this docket to incentivize, accelerate, and establish standardized regulatory frameworks for new research into nonhealing chronic wounds—specifically focusing on the distinct, severe pathophysiologies found in cancer patients, individuals living with diabetes, and the elderly. Chronic, nonhealing wounds represent a silent, devastating public health epidemic. Despite their massive prevalence, clinical development in wound care has historically lagged behind other major medical fields. The multi-morbid populations highlighted in this comment face unique physiological barriers that standard wound treatments fail to solve: 1. Cancer Patients: Malignant wounds, surgical complications, and wounds compounded by the side effects of systemic chemotherapy or radiation therapy face an entirely disrupted cellular environment. Radiation damages localized blood vessels and induces deep tissue fibrosis, while chemotherapy suppresses the bone marrow, depriving the wound bed of the immune cells and platelets necessary to kickstart natural tissue regeneration. 2. Patients with Diabetes: Diabetic foot ulcers (DFUs) are plagued by persistent, long-term inflammation, severe peripheral neuropathy (nerve damage), and microvascular disease. The impaired microcirculation prevents adequate oxygen and essential nutrients from reaching the affected tissue, leading to a catastrophic risk of deep bone infections (osteomyelitis) and lower-limb amputations. 3. The Elderly Population: Advanced age brings an onset of cellular senescence—where aging cells stop dividing but refuse to die, actively pumping out inflammatory signals that degrade the surrounding tissue. Combined with thinning skin and naturally diminished collagen production, the elderly are highly susceptible to debilitating, slow-healing pressure ulcers and venous leg ulcers. To meaningfully change the outlook for these patients, I request that the FDA prioritize the following initiatives within this regulatory framework: Establishment of Clear, Biomarker-Driven Endpoints: Traditional regulatory approval for wound healing treatments relies heavily on complete, 100% wound closure. For these complex, high-risk patient populations, the FDA should collaborate with researchers to validate surrogate endpoints, such as the early reduction of specific inflammatory biomarkers, rapid stabilization of the wound bed, or significant pain reduction, which reliably predict long-term healing success. Encouragement of Advanced Modalities and Combination Products: We need a regulatory pipeline designed to evaluate next-generation solutions, including smart bio-engineered tissue scaffolds, localized oxygen delivery systems, topical gene therapies, and advanced cellular/extracellular vesicle (exosome) therapies tailored to reverse tissue senescence. Incentivizing Diverse and Inclusive Clinical Trials: The FDA should issue clear guidance encouraging drug and device sponsors to actively enroll multi-morbid individuals—such as elderly patients with multiple chronic conditions or cancer survivors with history of radiation—rather than excluding them to achieve cleaner, less complex trial data. By modernizing regulatory standards and fostering targeted, collaborative research, the FDA has a historic opportunity to alleviate immense human suffering, drastically lower healthcare costs associated with extended hospitalizations, and prevent the profound loss of independence caused by chronic wounds. Thank you for your proactive leadership and dedication to bringing innovative care to our nation's most vulnerable patients.